Decreased galectin-3 expression in prostate cancer
dc.contributor.author | Pacis, Ronald A. | en_US |
dc.contributor.author | Pilat, Mary Josephine P. | en_US |
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.contributor.author | Wojno, Kirk J. | en_US |
dc.contributor.author | Raz, Avraham | en_US |
dc.contributor.author | Hogan, Victor | en_US |
dc.contributor.author | Cooper, Carlton R. | en_US |
dc.date.accessioned | 2006-04-19T13:48:51Z | |
dc.date.available | 2006-04-19T13:48:51Z | |
dc.date.issued | 2000-07-01 | en_US |
dc.identifier.citation | Pacis, Ronald A.; Pilat, Mary Josephine; Pienta, Kenneth J.; Wojno, Kirk; Raz, Avraham; Hogan, Victor; Cooper, Carlton R. (2000)."Decreased galectin-3 expression in prostate cancer." The Prostate 44(2): 118-123. <http://hdl.handle.net/2027.42/34754> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34754 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10881021&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Galectin-3 is a carbohydrate-binding protein whose level of expression has been shown to be correlated with metastatic potential in a number of different tumor types. The purpose of this investigation was to examine galectin-3 expression in several tumorigenic and nontumorigenic prostate cell lines and prostate tissue samples. METHODS The expression of galectin-3 in cell lines and tissue samples was evaluated by tissue immunohistochemistry and Western blot analysis. RESULTS Human cell lines PC-3M, PC-3, DU-145, PrEC-1, and MCF10A demonstrated the presence of galectin-3. Galectin-3 was not detected in TSU-pr1 and LNCaP by Western blot analysis. We furthered our studies by examining a series of human prostate tissue samples for expression of galectin-3. Overall, approximately 60–70% of the normal tissue examined demonstrated heterogenous expression of galectin-3. In stage II tumors, however, there was a dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10.5% (2/19) of these samples expressing this protein. Stage III tumors also demonstrated a decreased expression of galectin-3, although this downregulation was not as dramatic, with 35% of PIN samples and 52% of tumor tissue expressing galectin-3 ( P < 0.01). CONCLUSIONS These data demonstrate that galectin-3 is downregulated in prostate cancer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests different roles for galectin-3 in the progression of prostate cancer. Prostate 44:118–123, 2000. © 2000 Wiley-Liss, Inc. | en_US |
dc.format.extent | 1605678 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Decreased galectin-3 expression in prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan ; Section of Urology, Department of Surgery, St. John's Hospital, Detroit, Michigan ; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive-7308 CCGC, Ann Arbor, MI 48109-0946 | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan ; Department of Pathology, St. John's Hospital, Detroit, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Karmanos Cancer Institute and Wayne State University, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Karmanos Cancer Institute and Wayne State University, Detroit, Michigan | en_US |
dc.identifier.pmid | 10881021 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34754/1/4_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/1097-0045(20000701)44:2<118::AID-PROS4>3.0.CO;2-U | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.